Mini review on Methotrexate for inflammatory skin disorders in pediatrics according to consent management protocols

Nourizadeh, Maryam; Fattahi, Mahsa

Volume 14, Issue 4 (Volume 14, No 4 2024) jdc 2024, 14(4): 215-220 | Back to browse issues page

Mendeley

Zotero

RefWorks

Nourizadeh M, Fattahi M. Mini review on Methotrexate for inflammatory skin disorders in pediatrics according to consent management protocols. jdc 2024; 14 (4) :215-220
URL: http://jdc.tums.ac.ir/article-1-5691-en.html

Mini review on Methotrexate for inflammatory skin disorders in pediatrics according to consent management protocols

Maryam Nourizadeh ^*

¹, Mahsa Fattahi²

1- Immunology, Asthma and Allergy Research Center, Tehran University of Medical Sciences, Tehran, Iran , mnourizadeh80@gmail.com
2- Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract: (398 Views)

Methotrexate (MTX) is a freely available medication. However, regardless of extensive off-label consumption, FDA labeling does not include accepted for the consumption of MTX for many inflammatory skin diseases in pediatrics, containing morphea, psoriasis, atopic dermatitis, and alopecia areata. Lacking published healing recommendations makes the clinicians unsure about prescribing MTX in an off-label manner especially in children. Present study, was conducted to review the use of MTX to heal pediatric inflammatory skin disorders.
The evidence and consent based advices will assistance safe and successful use of MTX for the underserved population of pediatrics who may benefit from this valuable, time-honored medication.

Keywords: methotrexate, inflammatory skin disorder, pediatrics

Full-Text [PDF 220 kb] (134 Downloads)

Type of Study: Review | Subject: General
Received: 2024/03/17 | Accepted: 2024/02/4 | Published: 2024/02/4